SELLAS Life Sciences Group, Inc. (SLS) Stock Forecast
SLS analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 2 analysts
- Price target
- $32.50 average of analyst targets
- Upside to target
- +225.7% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.05
- 52-week range
- $1.39 – $15.46
SLS analyst ratings
2 analystsNumber of analysts at each rating.
SLS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SLS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.05 | −$0.05 | −$0.05 | −$0.06 | +16.7% | 1 |
| Current fiscal year (2026) | −$0.20 | −$0.20 | −$0.20 | −$0.25 | +20.0% | 1 |
| Next fiscal year (2027) | −$0.10 | −$0.20 | $0.00 | −$0.20 | +50.0% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SLS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $53.1M | $53.1M | $53.1M | 0.0% | 1 |
SLS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SLS revenue: reported and forecast
SLS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.06 | −$0.06 | −$0.06 | −$0.05 | −9.1% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.21 | −$0.21 | −$0.21 | −$0.21 | −$0.20 | −4.8% | 0 up · 0 down |
| Next fiscal year (2027) | −$0.15 | −$0.15 | −$0.12 | −$0.12 | −$0.10 | −33.3% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SLS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SLS beat in 8 of 12.
What analysts expect from SLS
2 analysts cover SELLAS Life Sciences; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $32.50, 225.7% above the latest close of $9.98. Analysts expect earnings of −$0.20 per share for 2026, +20.0% from a year earlier. For 2027 the average estimate is −$0.10 per share on revenue of $53.1 million. SELLAS Life Sciences beat the EPS estimate in 8 of the last 12 quarters.
Related: SLS income statement, SLS key metrics, SLS chart. See the SLS stock overview for the latest quote and news.
SLS forecast FAQ
What is SELLAS Life Sciences's price target?
The average analyst price target for SELLAS Life Sciences is $32.50, 225.7% above the latest close of $9.98.
Is SELLAS Life Sciences a buy, hold or sell?
Of 2 analysts covering SELLAS Life Sciences, 1 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is SELLAS Life Sciences's EPS forecast?
Analysts forecast −$0.20 per share for 2026 (range −$0.20 to −$0.20); for 2027 the estimate is −$0.10.
When does SELLAS Life Sciences report earnings?
SELLAS Life Sciences is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 after the market closes; the EPS estimate is $-0.05.
Does SELLAS Life Sciences usually beat earnings estimates?
SELLAS Life Sciences reported EPS at or above the analyst estimate in 8 of the last 12 quarters.